CRNX

Crinetics Pharmaceuticals, Inc.

CRNX | $42.98 -0.07% -0.07% 620K

(0.0% 1d) (-4.4% 1m) (140.7% 1y) (0.0% 2d) (0.0% 3d) (-1.6% 7d) (32.27% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 2,991,408,000
http://www.crinetics.com
Sec Filling | Patents | 68 employees

(United States) Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

endocrine endocrine diseases msa treatment

add to watch list Paper trade email alert is off

Press-releases

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-11 (Crawled : 20:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| -10.54% | O: -0.58% H: 2.05% C: -6.62%
nasdaq pharmaceuticals grants

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Published: 2024-03-19 (Crawled : 10:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 13.29% | O: 8.28% H: 11.95% C: 10.01%
study

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 5.45% | O: 0.81% H: 2.03% C: -1.41%
positive treatment topline trial results

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-11 (Crawled : 20:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 3.37% | O: -1.01% H: 1.48% C: -0.97%
pharmaceuticals grants

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 0.49% | O: 5.45% H: 1.89% C: -9.2%
year update pharmaceuticals financial results

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 6.18% | O: 15.27% H: 1.78% C: -8.34%
million pharmaceuticals

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Published: 2024-02-14 (Crawled : 21:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 18.34% | O: -0.55% H: 3.2% C: 2.24%
report year pharmaceuticals financial results

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 9.34% | O: -2.93% H: 0.0% C: -5.66%
nasdaq pharmaceuticals grants

Crinetics Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-11 (Crawled : 05:00) - crinetics.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 14.28% | O: -1.44% H: 1.9% C: 0.57%
nasdaq grants

Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-10 (Crawled : 22:00) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 14.28% | O: -1.44% H: 1.9% C: 0.57%
nasdaq pharmaceuticals grants

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-24-005061	4	2024-03-22	2024-03-20	Sell	M	10000	191667
0001209191-24-005061	4	2024-03-22	2024-03-20	Sell	M	4375	201667
0001209191-24-005061	4	2024-03-22	2024-03-20	Sell	S	714	27786
0001209191-24-005061	4	2024-03-22	2024-03-20	Buy	M	10000	38500
0001209191-24-005061	4	2024-03-22	2024-03-20	Sell	S	4375	28500
0001209191-24-005061	4	2024-03-22	2024-03-20	Buy	M	4375	32875